Moleculin Biotech (MBRX) provided an enrollment update with 60% of the target number of subjects for the first planned interim unblinding of data having consented to its pivotal Phase 2B/3 “MIRACLE” study of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia who are refractory to or relapsed (R/R) after induction therapy. The targeted number for the first unblinding of data is 45 subjects. Additional subjects continued to be identified by site investigators. This update is as of November 4, 2025, as identification and recruitment are ongoing. The Company expects to complete treatment of the first 45 subjects in the first quarter of 2026 with the initial unblinding of data thereafter.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech’s Strategic Advancements and Potential in Oncology: Buy Rating Justified by Key Partnerships and Promising Trials
- Moleculin Biotech Partners with UNC for Cancer Research
- Moleculin Biotech announces grant funded research evaluating Annamycin
- Moleculin Biotech Releases New Corporate Presentation
- Moleculin Biotech Secures Australian Patent for Annamycin